. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: J Subst Abuse Treat. 2019 Aug 16;107:29–37. doi: 10.1016/j.jsat.2019.08.009

Table 2.

Treatment Retention and Cocaine Use Outcomes

Treatment Retention and Outcome Variables	Galantamine						Placebo			Total Sample			Statistics: 3 group (8mg, 16mg, placebo)
Treatment Retention and Outcome Variables	8mg			16mg			Placebo			Total Sample			Statistics: 3 group (8mg, 16mg, placebo)
	Mean	SD	n	Mean	SD	n	Mean	SD	n	Mean	SD	n	F	df	p
A. Treatment/Protocol Adherence
Days in Treatment Protocol (week 1 to 12)^a	60.1	34.1	31	45.9	37.3	30	58.1	34.2	32	54.8	35.4	93	1.46	2,90	0.24
Days in Treatment Protocol (week 4 to 12)^b	38.2	23.5	31	27.6	26.1	30	36.3	24.0	32	34.2	24.7	93	1.62	2,90	0.20
Days of Data Reported on Substance Use Calendar (TLFB) (week 4 to 12)^b	47.2	15.7	25	34.9	25.1	21	41.9	21.1	26	41.7	21	72	2	2,69	0.14
% Urines Submitted (of Expected) (week 4 to 12)^b	85.8	21.4	24	77.9	22	17	84.4	21.6	24	83.2	21.5	65	0.71	2,62	0.50
% Clinic/Medication Dispensing Visits Attended (of Expected) (week 4 to 12)^{b, c}	71.9	44.3	30	48.2	48	29	68.8	43.2	31	63.2	45.9	90	2.38	2,87	0.10
B. Cocaine Use Outcomes
% Negative Cocaine Urines (week 4 to 12)^b	31.0	36.8	23	22.9	31.1	17	28.1	36.6	24	27.8	34.9	64	0.25	2,62	0.78
% Days Cocaine Abstinence (self-report) (week 4 to 12)^b	27.9	25.5	22	29	21.3	15	29.3	27.7	24	28.7	25.1	61	0.02	2,59	0.98
Longest Consecutive Days Cocaine Abstinence (self-report) (week 4 to 12)^b	13.9	14.7	25	8.2	10.1	21	13.4	15.2	26	12.1	13.8	72	1.16	2,69	0.32

Week 1 to 12 encapsulates the full galantamine treatment period, including titration. Week 0, where all groups received placebo, is not included.

Week 4 to 12 is restricted to the galantamine treatment period following titration, therefore the group randomized to 16mg galantamine were receiving 16mg galantamine/day during this time.

The pills (galantamine or placebo) were dispensed at each clinic/medication dispensing visit: participants were observed (by a member of the research team) ingesting that day’s pill(s), then were given take-home pills to cover them until the next scheduled clinic visit. CM payments were based on adherence with this visit protocol.